Status:
ACTIVE_NOT_RECRUITING
Clinic Navigation and Home Visits to Improve Guideline-based Care and Outcomes in Low Income Minority Adults With Asthma
Lead Sponsor:
University of Pennsylvania
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Asthma-related deaths are more numerous among low-income minority patients and older adults with chronic diseases. Guidelines for asthma management have not addressed the needs of these groups. The in...
Detailed Description
Asthma, a chronic but treatable disease, affects 18.7 million US adults. Asthma-related deaths, hospitalizations, and ED visits are more prevalent in low-income and minority patients, especially Afric...
Eligibility Criteria
Inclusion
- Female or male \> 18 years and living in a Philadelphia neighborhood in which at least 20% of households have incomes below the federal poverty level (19104, 19120, 19121, 19122, 19124, 19125, 19131, 19132, 19133, 19134, 19139, 19140, 19141, 19142, 19143, 19144, 19145, 19146, 19153, 19151)
- A patient in a participating clinic
- Doctor's diagnosis of asthma
- Prescribed an inhaled corticosteroid for asthma
- Required prednisone or an Emergency Department (ED) visit or hospitalization for asthma within 12 months before enrollment.
- Some patients with a diagnosis of asthma and prescribed inhaled corticosteroid may also have mention of Chronic Obstructive Pulmonary Disease (COPD) in their record, particularly if they smoke. Asthma and COPD are both heterogeneous diseases, and may be impossible to distinguish by clinical characteristics.Both COPD and asthma can have evidence of reversible obstruction and also of irreversible obstruction. It is important not to exclude these patients, sometimes called overlap patients as they may benefit from these interventions.
Exclusion
- Severe psychiatric or cognitive problems making it impossible to understand or carry out the protocol;
- Excluded are those with other chronic lung diseases: lung cancer, cystic fibrosis, heart failure, chronic bronchitis, pulmonary hypertension, a candidate or recipient for lung transplant, a history of bronchial thermoplasty.
- Excluded are those with more than 20 pack year tobacco use.
Key Trial Info
Start Date :
August 21 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2026
Estimated Enrollment :
367 Patients enrolled
Trial Details
Trial ID
NCT04023422
Start Date
August 21 2019
End Date
April 30 2026
Last Update
May 18 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania Health Center
Philadelphia, Pennsylvania, United States, 19104
2
University of Pennsylvania Health System
Philadelphia, Pennsylvania, United States, 19104